Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
IPO Year: 2020
Exchange: NASDAQ
Website: inhibikase.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/15/2021 | $12.00 | Buy | JonesTrading |
BOSTON and ATLANTA, Sept. 1, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders as well as other diseases arising from protein kinases, today announced the appointment of Ms. Gisele Dion to its Board of Directors, effective September 1, 2022. Ms. Dion will serve as chair of the Audit Committee and a member of the Compensation Committee following the retirement of Ms. Elizabeth O'Farrell from the Company's Board of Directors, effective immediately.
BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the second quarter ended June 30, 2024 and highlighted recent developments. "The first half of 2024 has showcased the strength of our pipeline through the continued execution of key milestones for both risvodetinib (risvo) and IkT-001Pro," said Dr. Milton H. Werner, President and Chief Executive Officer of Inhibik
BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 15, 2024, to provide a corporate update and review the financial results. The
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the company has completed enrollment in the Phase 2 ‘201' trial evaluating the safety and tolerability of risvodetinib ("risvo"), a potent selective c-Abl inhibitor, for treatment in untreated Parkinson's patients. The company expects to report trial results in the fourth quarter of 2024. "The completion of enrollment for the 201 Trial
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced expansion of its therapeutic pipeline and multiple updates to its Research and Development programs. "At Inhibikase we have let fundamental scientific discoveries drive identification of new product candidates that could transform t
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,672,452 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered Series
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the first quarter ended March 31, 2024 and highlighted recent developments. "2024 is shaping up to be a year of clinical and regulatory execution as we advance our core programs towards important inflection points," said Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase. "The Phase 2 201 t
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission ("SEC") with respect to the withdrawal of the Company's Registration Statement on Form S-1 (File No. 333-278844) that it filed with the SEC originally on April 19, 2024. The Registration Statement has not been declared effective by the SEC, and no s
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company has received final meeting minutes from its recent pre-IND meeting with the Division of Cardiology and Nephrology of the U.S. Food and Drug Administration (FDA) for IkT-001
BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders. Dear Fellow Shareholders of Inhibikase Therapeutics: 2024 has been off to a productive start for Inhibikase. Our 201 Trial is approximately 75% enrolled, with the last patient anticipated to enter the trial in June. We have had consistent and constructive interactions with the U.S. Food and Drug Administration
BOSTON and ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company will meet with the Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN) in the Division of Cardiology and Nephrology (DCN) at the U.S. Food and Drug Administration (FDA) for a Pre-IND meeting to discuss IkT-001Pro ("Pro") as a treatment for Pulmonary Arterial Hypertension (PAH). The meeting will be held
4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and lowers the price target from $27 to $23.
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.79) by 7.59 percent. This is a 25.51 percent increase over losses of $(0.98) per share from the same period last year.
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission ("SEC") with respect to the withdrawal of the Company's Registration Statement on Form S-1 (File No. 333-278844) that it filed with the SEC originally on April 19, 2024. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offerin
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension –BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company has received final meeting minutes from its recent pre-IND meeting with the Division of Cardiology and Nephrology of the U.S. Food and Drug Administration (FDA) for IkT-001Pro (
Shares of Vaxxinity, Inc. (NASDAQ:VAXX) fell sharply during Monday's session after the company announced its intention to voluntarily delist and deregister its Class A common stock. Vaxxinity shares dipped 54.8% to $0.2150 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Matterport, Inc. (NASDAQ:MTTR) shares jumped 184% to $4.93. CoStar Group announced plans to acquire Matterport in a cash and stock transaction valued at $5.50 per share reflecting an estimated $1.6 billion value. NewGenIvf Group Limited (NASDAQ:NIVF) climbed 126% to $1.67 after the company signed a non-binding term sheet for a potential reverse merger with European Wellness Inv
Gainers NKGen Biotech (NASDAQ:NKGN) shares rose 33.8% to $1.48 during Monday's regular session. The company's market cap stands at $33.7 million. The company's, Q4 earnings came out 4 days ago. MSP Recovery (NASDAQ:LIFW) shares rose 29.74% to $1.23. The company's market cap stands at $19.5 million. Assure Hldgs (NASDAQ:IONM) stock increased by 24.31% to $0.55. The market value of their outstanding shares is at $4.9 million. ProKidney (NASDAQ:PROK) stock increased by 22.79% to $2.5. The company's market cap stands at $154.3 million. iSpecimen (NASDAQ:ISPC) shares increased by 19.32% to $0.34. The company's market cap stands at $3.1 million. GlucoTrack (NASDAQ:GCTK) stock moved upwards b
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders.Dear Fellow Shareholders of Inhibikase Therapeutics:2024 has been off to a productive start for Inhibikase. Our 201 Trial is approximately 75% enrolled, with the last patient anticipated to enter the trial in June. We have had consistent and constructive interactions with the U.S. Food and Drug Administration for IkT-001Pro, culminating in the recent completion of a pr
10-Q - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
424B3 - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
EFFECT - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
DEFA14A - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
DEF 14A - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
S-1 - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
PRE 14A - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
D - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
JonesTrading initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $12.00
BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 15, 2024, to provide a corporate update and review the financial results. The
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the first quarter ended March 31, 2024 and highlighted recent developments. "2024 is shaping up to be a year of clinical and regulatory execution as we advance our core programs towards important inflection points," said Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase. "The Phase 2 201 t
BOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent developments. "2023 was a year of clinical execution across our pipeline, culminating in the recent pre-NDA meeting with the FDA for IkT-001Pro and robust enrollment of untreated Parkinson's patients in our 201 Trial evaluating Risvod
BOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the third quarter ended September 30, 2023 and highlighted recent developments. "We are very pleased with the progress of the last quarter," noted Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase. "Our efforts to improve drug delivery for protein kinase inhibitors brought IkT-001Pro to pre
This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter" rather than "third quarter." BOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the third quarter ended September 30, 2023, on Tuesday, November 14,
BOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the third quarter ended September 30, 2023, on Tuesday, November 14, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Wednesday, November 15, 2023, to provide a corporate update and review the financial result
Company to host conference call on Tuesday, August 15, 2023 at 8:00 a.m. ET BOSTON and ATLANTA, Aug. 14, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the second quarter ended June 30, 2023 and highlighted recent developments. "We have made significant clinical progress in the fi
BOSTON and ATLANTA, Aug. 7, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2023, on Monday, August 14, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023, to provide a corporate update and review the financial results.
BOSTON and ATLANTA, May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the first quarter ended March 31, 2023, on Monday, May 15, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Tuesday, May 16, 2023, to provide a corporate update and review the financial results.
BOSTON and ATLANTA, March 23, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the fourth quarter and full-year ended December 31, 2022 on Friday, March 31, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Monday, April 3, 2023, to provide a corporate update and review the financial results.
SC 13D - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
SC 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
SC 13D - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
SC 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
SC 13D - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
SC 13D - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
SC 13D - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
SC 13G - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
SC 13G - Inhibikase Therapeutics, Inc. (0001750149) (Subject)